Changes in estrogen-sensitive hemostatic biomarkers (nAPCsr, nTM sr, and SHBG) among those who stopped using CHCs
| . | Women who stopped using CHCs (n = 66) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| nAPCsr . | nTMsr . | SHBG (nmol/L) . | |||||||
| n . | Mean (SD) . | Relative decrease . | n . | Mean (SD) . | Relative decrease . | n . | Mean (SD) . | Relative decrease . | |
| Baseline | 64 | 4.11 (2.06) | Ref | 63 | 2.53 (1.04) | Ref | 66 | 167 (103) | Ref |
| 1 wk | 62 | 2.34 (1.50) | 62.1% | 63 | 1.69 (0.88) | 59.7% | 66 | 123 (76.0) | 39.8% |
| 2 wk | 56 | 1.67 (0.98) | 85.8% | 60 | 1.38 (0.69) | 81.3% | 66 | 81.9 (41.8) | 76.2% |
| 4 wk | 50 | 1.64 (1.17) | 86.7% | 55 | 1.32 (0.66) | 85.5% | 64 | 69.0 (35.3) | 87.8% |
| 6 wk | 46 | 1.37 (0.84) | 96.4% | 54 | 1.24 (0.65) | 91.3% | 61 | 59.5 (31.7) | 96.4% |
| 12 wk | 45 | 1.27 (0.82) | 100% | 59 | 1.11 (0.58) | 100% | 66 | 55.4 (26.7) | 100% |
| . | Women who stopped using CHCs (n = 66) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| nAPCsr . | nTMsr . | SHBG (nmol/L) . | |||||||
| n . | Mean (SD) . | Relative decrease . | n . | Mean (SD) . | Relative decrease . | n . | Mean (SD) . | Relative decrease . | |
| Baseline | 64 | 4.11 (2.06) | Ref | 63 | 2.53 (1.04) | Ref | 66 | 167 (103) | Ref |
| 1 wk | 62 | 2.34 (1.50) | 62.1% | 63 | 1.69 (0.88) | 59.7% | 66 | 123 (76.0) | 39.8% |
| 2 wk | 56 | 1.67 (0.98) | 85.8% | 60 | 1.38 (0.69) | 81.3% | 66 | 81.9 (41.8) | 76.2% |
| 4 wk | 50 | 1.64 (1.17) | 86.7% | 55 | 1.32 (0.66) | 85.5% | 64 | 69.0 (35.3) | 87.8% |
| 6 wk | 46 | 1.37 (0.84) | 96.4% | 54 | 1.24 (0.65) | 91.3% | 61 | 59.5 (31.7) | 96.4% |
| 12 wk | 45 | 1.27 (0.82) | 100% | 59 | 1.11 (0.58) | 100% | 66 | 55.4 (26.7) | 100% |
The relative decrease was calculated as the proportion of the absolute difference between baseline and 12 weeks that was obtained at each study time point.
Ref, reference group.